Company: Lake Boon Pharmaceutical Consulting
Job title: Principal
Mark retired in 2022 after 31 years in the Pharmaceutical Industry, most recently working for Novartis where he provided support to biodistribution and immunogenicity assessments for Gene Therapies.
Detecting Pre-Existing Immunity to AAV Gene Therapies 11:00 am
One of the inherent challenges to effective AAV gene therapy treatment is the prior exposure and neutralizing antibody (NAb) generation in a large number of target populations. The methods used for testing for seropositivity prior to transfer remains a hotly-debated topic, with no universal test or titer currently deployed as an industry standard for detecting…Read more
day: Pre-Conference Day